Recently, Borui Biopharmaceutical (Suzhou) Co., Ltd. (hereinafter referred to as "Borui Pharmaceutical") announced the completion of 5.500 million pre-IPO round of financing, this round of financing led by Sequoia Capital China Fund, Honghui Capital, Guangfa dry and participate in investment.
Borui Pharmaceutical is a "national high-tech enterprise" founded by Dr. Yuan Jiandong, a special expert of the "Thousand Talents Program". It is committed to the development and production of original new drugs and difficult generic drugs to find solutions for unmet clinical needs.With its strong R & D strength as the cornerstone of development, Borui Pharmaceutical has achieved rapid development by relying on its global registration and commercialization capabilities, as well as its cGMP production quality system in line with international standards, and has become a pharmaceutical group covering R & D, production, and sales of the entire industry chain.Borui Pharmaceutical has set up a research and development team of 300 people with R & D investment exceeding 25% of its operating income each year; the production quality management system has passed the certified cGMP in Europe, the United States, Japan, and South Korea; it has first listed entecavir, caspofungin, anidulafungin, and other products in the European and American markets; it has successfully developed high-end generic drugs such as eribulin, trabetidine, and fondaparinux, and has established a product line with global competitive advantages in the fields of anti-tumor, super antibiotics, and intravenous iron supplementation.Including SDIC, CICC, Huatai, the cornerstone of a number of well-known investment funds stationed.
Yuan Jiandong, chairman of the company, said that the funding for this round of financing is mainly used in two aspects: on the one hand, it is invested in the development of innovative drugs and clinical.The company has previously stocked up some "new global" originals, and the project has been slow to advance due to the rolling development of profits from its own business.Incremental funding will play a positive role in the rapid advancement of these innovative drugs.On the other hand, some of the funds for this round of financing will be used to increase the capacity of raw material factories and the construction of injection factories, which produce complex injections for the global market and are the main source of future profits for the company.Xu Qiang, vice president of Sequoia Capital China Fund, said: "'Consistency assessment + centralized procurement' will accelerate the reshuffle of the pharmaceutical industry.We value the core value of the enterprise and the competitive advantage of technical barriers.Borui Bio focuses on high-end raw material medicines and preparations with few competitors and particularly difficult technologies, and has a clear positioning. Based on multi-chiral drug platforms, fermentation semi-synthetic platforms, non-biological macromolecular platforms, and targeted polymer coupling platforms, it has developed and stocked a number of products with high technical barriers. At the same time, it has built a complete industrial chain from difficult intermediates, high-end raw material medicines to preparations, and has a strong competitive advantage in future industrial integration.We are optimistic about the potential and sustained momentum of Borui Pharmaceutical's long-term development and are willing to support the long-term and steady development of such outstanding enterprises."We are pleased to work with Sequoia Capital China Fund to invest and serve Borui Pharmaceuticals," said He Xing, partner of Honghui Capital.Borui Pharmaceutical is a high-tech pharmaceutical company driven by R & D. Its core products are in the leading position in the global market, and its management team has rich experience. Especially under the leadership of Chairman Yuan Jiandong, Borui Pharmaceutical has brought into full play the competitive advantage of two-wheel drive of core technology capabilities and operational execution capabilities."
About Sequoia Capital China Fund
Sequoia Capital has always been committed to helping entrepreneurs become evergreen companies, bringing rich global resources and valuable historical experience to member companies.For 47 years, Sequoia Capital has invested in a number of innovative companies and industry leaders.Sequoia Capital China Fund, as an entrepreneur behind entrepreneurs, focuses on investment opportunities in four directions: technology/media, healthcare, consumer goods/services, and industrial technology.In the past 14 years, Sequoia Capital China Fund has invested more than 500 companies with distinctive technical features, innovative business models, and high growth and development potential.
About Honghui Capital
Honghui Capital is an investment fund focused on the healthcare industry, which manages five main funds in both US dollar and RMB.Honghui Capital's investment focuses on biomedicine, medical devices, etc.The investment portfolio includes: Mindray Medical (300760), Yuyue Medical (002223), WuXi PharmaTech (603259), Kanglong Huacheng (300759), Pioneering Pharmaceuticals, Baiyang Pharmaceutical, Shengxiang Biological, Kemei Diagnostics, Ma Yi Dental, Chaoju Ophthalmology and other high-quality enterprises.
On GF & H
GF & E Investment Co., Ltd. is GF Securities Limited (stock code: 000776.SZ, 1776.HK) a wholly owned alternative investment subsidiary.Guang Fa Gan and currently mainly engaged in equity investment business, with industry-leading equity investment scale and capabilities, and committed to helping high-quality customers through capital operations to grow into leaders in the subdivision industry.
The medical field is one of the industry directions of Guangfa Gansu and its key layout. It has invested in Qingdao Baiyang, Kanglong Huacheng, Kawai Bio, Yueyang Pharmaceutical, and Akang Health.